Healthcare >> CEO Interviews >> May 22, 2001
ANGUS C. RUSSELL, Group Finance Director of Shire Pharmaceuticals Group
Plc, joined the company in December 1999 and is responsible for Finance,
IT and Corporate Communications. Mr. Russell served his articles with
Coopers & Lybrand and qualified as a Chartered Accountant in 1979. He
joined ICI's Pharmaceuticals Division in 1980 in a management accounting
role and subsequently a production accounting role. In 1985 he moved to
ICI's Petrochemicals and Plastics Division, firstly in a business
accounting role, subsequently transferring to a senior product marketing
position in 1986. In 1988, he moved to ICI's Treasury Department in
London, where he was responsible for group long-term funding and
corporate financing activities in the Middle East and Africa. In March
1990 he transferred to the Corporate Planning Department where he worked
on several global business strategies, executed a number of M & A deals,
coordinated defense work and oversaw business activities in the
Americas, Middle East, Africa, India and Pakistan. Mr. Russell was
assigned to work on group restructuring during 1991 and subsequently
became a member of the team which planned and executed the ICI de-merger
and Zeneca flotation. On February 25 1993, he was appointed to the
position of Group Investor Relations Manager for ZENECA Group Plc. On
January 1, 1995, he was appointed Group Treasurer for ZENECA Group Plc
with responsibility for Treasury, Investor Relations, IC Insurance and
was also appointed a Trustee Director of the ZENECA UK Pension Fund. Mr.
Russell played a key role in the merger of Astra and Zeneca in 1998 and
was subsequently appointed VP of Corporate Finance. In 1999 he was part
of a small team which negotiated the Syngata agrochemicals merger with
Novartis. Profile
stage?
Mr. Russell: Shire was founded as a UK-based company in 1986. At that
time it was mainly privately owned by
